What does FALIPHARMA do?

FALIPHARMA is a pharmacy in Sambreville. Private Limited, started on 31 August 1982, 2 establishments.

What is the address of FALIPHARMA?

The registered office of FALIPHARMA is located at Rue J.J. Merlot(FAL) 3 box A, 5060 Sambreville.

Is FALIPHARMA still active?

Yes. According to the CBE (30 October 2026) FALIPHARMA is active, legal situation “Normale toestand”, started on 31 August 1982.

Is FALIPHARMA registered on Peppol?

Yes, FALIPHARMA is registered on the Peppol network with ID 0208:0422990373.

What is the enterprise number of FALIPHARMA?

The enterprise number of FALIPHARMA is BE0422990373.

When was FALIPHARMA founded?

FALIPHARMA was founded on 31 August 1982.

Who are the directors of FALIPHARMA?

According to the 2025 annual accounts, the directors of FALIPHARMA are: MARIE SCAILQUIN ANNE, JAROLINE PHARMA SRL.

Is FALIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 August 1982; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did FALIPHARMA make in 2025?

FALIPHARMA posted a profit after taxes of € 47,771 in financial year 2025.

What is the revenue of FALIPHARMA?

As a small company, FALIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 269,699.

How much does an employee at FALIPHARMA earn?

The average wage cost per full-time employee at FALIPHARMA was € 53,900 in 2025: staff costs of € 161,730 for 3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does FALIPHARMA have?

According to the 2025 annual accounts, FALIPHARMA has 3 full-time equivalents (FTE).

FALIPHARMA (Private Limited) - Sambreville - BE0422990373

Dossier FALIPHARMA, printed on 30 October 2026 from databakkes.be/en/0422990373/falipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FALIPHARMA from Sambreville, company number BE0422990373, closed financial year 2025 with a result of € 47,771 after tax. For that financial year FALIPHARMA recorded a gross margin of € 269,699 and equity of € 324,777. Compared with financial year 2024, the result moved from € 32,672 to € 47,771. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Growing

€ 324,777

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 47,771

▲ 46% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 243,310

▲ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 305,777.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 161,730

▲ 2% vs 2024

€ 53,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,421

▲ € 4,328 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 152,387

▲ 28% vs 2024

€ 51,026 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 37,419

▲ 9% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 34,322

▼ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 235,718 Gross margin 2022: € 235,718 First fiscal year in the series	€ 213,640 Gross margin 2023: € 213,640 ▼ 9% vs 2022 (€ 235,718) Unfavourable step	€ 243,295 Gross margin 2024: € 243,295 ▲ 14% vs 2023 (€ 213,640) Favourable step	€ 269,699 Gross margin 2025: € 269,699 ▲ 11% vs 2024 (€ 243,295) Favourable step	▲ 11%
Profit after taxes	€ 7,664 Profit after taxes 2022: € 7,664 First fiscal year in the series	€ 18,854 Profit after taxes 2023: € 18,854 ▲ 146% vs 2022 (€ 7,664) Favourable step	€ 32,672 Profit after taxes 2024: € 32,672 ▲ 73% vs 2023 (€ 18,854) Favourable step	€ 47,771 Profit after taxes 2025: € 47,771 ▲ 46% vs 2024 (€ 32,672) Favourable step	▲ 46%
Equity	€ 223,848 Equity 2022: € 223,848 First fiscal year in the series	€ 242,702 Equity 2023: € 242,702 ▲ 8% vs 2022 (€ 223,848) Favourable step	€ 277,007 Equity 2024: € 277,007 ▲ 14% vs 2023 (€ 242,702) Favourable step	€ 324,777 Equity 2025: € 324,777 ▲ 17% vs 2024 (€ 277,007) Favourable step	▲ 17%
Total debts	€ 407,122 Total debts 2022: € 407,122 First fiscal year in the series	€ 419,186 Total debts 2023: € 419,186 ▲ 3% vs 2022 (€ 407,122) Unfavourable step	€ 404,580 Total debts 2024: € 404,580 ▼ 3% vs 2023 (€ 419,186) Favourable step	€ 407,198 Total debts 2025: € 407,198 ▲ 1% vs 2024 (€ 404,580) Unfavourable step	▲ 1%
Cash	€ 204,086 Cash 2022: € 204,086 First fiscal year in the series	€ 106,985 Cash 2023: € 106,985 ▼ 48% vs 2022 (€ 204,086) Unfavourable step	€ 202,241 Cash 2024: € 202,241 ▲ 89% vs 2023 (€ 106,985) Favourable step	€ 243,310 Cash 2025: € 243,310 ▲ 20% vs 2024 (€ 202,241) Favourable step	▲ 20%
Land & buildings	€ 170,581 Land & buildings 2022: € 170,581 First fiscal year in the series	€ 156,362 Land & buildings 2023: € 156,362 ▼ 8% vs 2022 (€ 170,581) Unchanged	€ 142,143 Land & buildings 2024: € 142,143 ▼ 9% vs 2023 (€ 156,362) Unchanged	€ 128,521 Land & buildings 2025: € 128,521 ▼ 10% vs 2024 (€ 142,143) Unchanged	▼ 10%
Retained profit	€ 204,848 Retained profit 2022: € 204,848 First fiscal year in the series	€ 223,702 Retained profit 2023: € 223,702 ▲ 9% vs 2022 (€ 204,848) Favourable step	€ 258,007 Retained profit 2024: € 258,007 ▲ 15% vs 2023 (€ 223,702) Favourable step	€ 305,777 Retained profit 2025: € 305,777 ▲ 19% vs 2024 (€ 258,007) Favourable step	▲ 19%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 800) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 136,614 Bank debt 2022: € 136,614 First fiscal year in the series	€ 128,061 Bank debt 2023: € 128,061 ▼ 6% vs 2022 (€ 136,614) Favourable step	€ 119,336 Bank debt 2024: € 119,336 ▼ 7% vs 2023 (€ 128,061) Favourable step	€ 152,387 Bank debt 2025: € 152,387 ▲ 28% vs 2024 (€ 119,336) Unfavourable step	▲ 28%
Balance sheet total	€ 630,970 Balance sheet total 2022: € 630,970 First fiscal year in the series	€ 661,889 Balance sheet total 2023: € 661,889 ▲ 5% vs 2022 (€ 630,970) Unchanged	€ 681,587 Balance sheet total 2024: € 681,587 ▲ 3% vs 2023 (€ 661,889) Unchanged	€ 731,975 Balance sheet total 2025: € 731,975 ▲ 7% vs 2024 (€ 681,587) Unchanged	▲ 7%
Employees (FTE)	3 Employees (FTE) 2022: 3 First fiscal year in the series	3 Employees (FTE) 2023: 3 Unchanged (3) Unchanged	3 Employees (FTE) 2024: 3 Unchanged (3) Unchanged	3 Employees (FTE) 2025: 3 Unchanged (3) Unchanged

Key figures of FALIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FALIPHARMA?

What happened at FALIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 24, 2026 New annual accounts for financial year 2025: profit of € 47,771 (▲ 46% vs 2024). Source: NBB ↗
2026 JAROLINE PHARMA SRL became a director. NBB
2015 MARIE SCAILQUIN ANNE became a director. NBB
Sep 1, 1982 New establishment in Sambreville. KBO
Sep 1, 1982 New establishment in Sambreville. KBO
Aug 31, 1982 Start of the company according to the CBE. KBO

In short

From € 7,664 profit in 2022 to € 47,771 profit in 2025.

Paid € 40,691 in corporate taxes since 2022.

Best year ever: 2025, with € 47,771 profit.

On average € 89,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Jaroline Pharma 100%

The stake of Jaroline Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FALIPHARMA

Behind FALIPHARMA are MARIE SCAILQUIN ANNE and JAROLINE PHARMA SRL. The shares are held by Jaroline Pharma (100%).

Directors

According to the 2025 annual accounts

MARIE SCAILQUIN ANNE

Director

since 2015

JAROLINE PHARMA SRL

Director · represented by RUTH CELINE

since 2026

Shareholders

Jaroline Pharma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue J.J. Merlot(FAL) 3 box A

5060 Sambreville

2.020.968.868

Rue J.J. Merlot(FAL) 23

5060 Sambreville

Active since 1 September 1982

2.020.968.967

Rue de Fosses(FAL) 17

5060 Sambreville

Active since 1 September 1982

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

BDG NAMUR

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0422.990.373

VAT number

BE 0422.990.373

Registered office

Rue J.J. Merlot(FAL) 3 bus A, 5060 Sambreville

Names & denominations

FALIPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

31 August 1982

Peppol

Active · Active since 11 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

FALIPHARMA

Financials

What happened to FALIPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions